跳至主要内容
搜索

儿童肿瘤学小组试验 AALL1231: 硼替佐米治疗新诊断 T 细胞急性淋巴细胞白血病和淋巴瘤的 III 期临床试验.

Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic
白血病 (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome
inhibitor bortezomib was examined in the Children’s Oncology Group phase
III clinical trial AALL1231, which also attempted to reduce the use of
prophylactic cranial radiation (CRT) in newly diagnosed T-ALL.

关闭菜单